Colleen O'Connor

Colleen O'Connor is an accomplished biotechnology executive with extensive experience in research and development in oncology. As the Founder and CEO of CAVU Biotherapies from July 2015 to May 2024, Colleen led a revenue-generating biotech company focused on patented platform technology, earning recognition for leadership. Prior experience includes serving as a Research Investigator at MD Anderson Cancer Center, where Colleen designed and completed translational clinical trials for CAR T-cell therapies and developed genomic biomarkers for cancer prognosis. A solid foundation in aquatic biology as an Aquatic Biologist at Newport Aquarium complemented Colleen's scientific expertise, which is underpinned by a PhD in Toxicology with a specialization in Immunology from the University of Kentucky College of Medicine and a BS in Marine Science and Biology from the University of Miami.